

A CASE OF RECURRENT MYOPERICARDITIS SECONDARY TO COVID-19 VACCINATION

Jason Chang, M.D.¹, Mingwei Yu, M.D.¹, Uzochukwu Ibe, M.D.², Hasith
Wickramasinghe, M.D.¹, Matthew T. Barbery, M.D.¹

¹Department of Medicine, ²Department of Cardiology, Danbury Hospital

“Case vignettes”

Case Presentation:

24-year-old male presented with worsening midsternal chest pain for 1 day. His past medical history includes obesity, ADHD, asthma, and COVID-19 vaccine-related myopericarditis. He takes no medications at home and denies any uses of tobacco, alcohol, or illicit substances. He was previously diagnosed with myopericarditis attributed to COVID-19 vaccination about 8 months prior, after developing chest pain 2 days following administration of his second dose of Moderna vaccine. He did not receive additional workups or continuous treatment at the time due to noncompliance. Afterwards, he had experienced occasional chest pain which usually responded to NSAIDs use. He did not receive booster dose for COVID. He described his current symptoms as sharp, 3/10 in severity, non-radiating, aggravated by positional changes and deep inspiration, and not associated with any other symptoms. In the emergency department he was found to have markedly elevated cardiac enzymes, moderately elevated acute inflammatory markers, and ST-segment elevations in the inferolateral leads. Due to high likelihood of recurrent myopericarditis he was admitted to the hospital and administered aspirin, colchicine, and ibuprofen. Echocardiogram was obtained which revealed ejection fraction of 55-60% and hypokinesis of the basal inferior wall. He experienced significant clinical improvement with medical therapy and was discharged from the hospital within 48 hours with instructions to continue colchicine and ibuprofen.

Discussion:

Myopericarditis is a rare complication of COVID-19 vaccination and most cases are mild and short-lived. The condition is considered self-limited and generally does not require any treatment. However, in patients with persistent or recurrent myopericarditis due to COVID-19 vaccination, management is similar to pericarditis from common etiologies with combination of colchicine and NSAIDs

Conclusion:

Colchicine combined with NSAIDs is the mainstay of treatment for recurrent myopericarditis caused by COVID-19 vaccination.